Network pharmacology research (Baoyu et al., 2020) indicated that the key targets of the Yishenyangsui granule in the treatment of DCM were STAT3, AKT1, JUN, MAPK1, IL-6, and RELA. This evidence concerns the gene JUN and familial dilated cardiomyopathy.